Pogach L M, Lee Y, Giglio W, Naumoff M, Huang H F
Department of Medicine, East Orange Veterans Administration Medical Center, NJ 07019.
Cancer Chemother Pharmacol. 1989;24(3):177-80. doi: 10.1007/BF00300239.
The present study was undertaken to determine if prior administration of zinc acetate (ZnAc) or copper sulfate (CuSO4) could prevent pituitary, Leydig, or Sertoli cell dysfunction subsequent to cisplatin administration in adult Sprague-Dawley rats. Animals were given cisplatin at a dose of 2 mg/kg daily for 5 days, with or without the i.p. administration of ZnAc (6 mg/kg per day) or CuSO4 (5 mg/kg per day), beginning 5 days prior to and continuing through the administration of cisplatin. Control animals were given vehicle, ZnAc1, or CuSO4. Animals were sacrificed 1 week after the initial cisplatin injection. Cisplatin administration resulted in suppressed serum luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels as well as a 77% reduction in serum testosterone and an 82% reduction in testicular testosterone. The concomitant administration of either ZnAc or CuSO4 did not result in a significant difference relative to animals receiving cisplatin alone, although administration of both cations alone significantly reduced testicular testosterone content. Serum androgen-binding protein (ABP) was not significantly lowered in any treatment group. There was a marked reduction of 57% in testicular ABP content relative to control values subsequent to cisplatin administration. This reduction was partially prevented by ZnAc treatment: the testicular ABP concentration was only 15% lower than that in controls (not significant). Since the cisplatin-induced reduction in serum FSH was not altered by ZnAc pretreatment, we conclude that the near normalization of testicular ABP content may be evidence of improved Sertoli cell function. In contrast, cisplatin-induced decreases in the serum gonadotropins and testicular androgens were not lessened by pretreatment with either cation. Further studies may be warranted to determine whether ZnAc pretreatment has a beneficial effect on spermatogenesis during cisplatin treatment.
本研究旨在确定预先给予醋酸锌(ZnAc)或硫酸铜(CuSO4)是否可以预防顺铂给药后成年Sprague-Dawley大鼠垂体、睾丸间质细胞或支持细胞功能障碍。动物每日腹腔注射剂量为2mg/kg的顺铂,持续5天,在顺铂给药前5天开始并持续至顺铂给药结束,同时或不腹腔注射ZnAc(每天6mg/kg)或CuSO4(每天5mg/kg)。对照动物给予赋形剂、ZnAc或CuSO4。在首次注射顺铂1周后处死动物。顺铂给药导致血清黄体生成素(LH)和卵泡刺激素(FSH)水平降低,血清睾酮降低77%,睾丸睾酮降低82%。与单独接受顺铂的动物相比,同时给予ZnAc或CuSO4并没有导致显著差异,尽管单独给予两种阳离子均显著降低了睾丸睾酮含量。任何治疗组的血清雄激素结合蛋白(ABP)均未显著降低。顺铂给药后,睾丸ABP含量相对于对照值显著降低了57%。ZnAc治疗部分预防了这种降低:睾丸ABP浓度仅比对照低15%(无显著差异)。由于ZnAc预处理并未改变顺铂诱导的血清FSH降低,我们得出结论,睾丸ABP含量接近正常化可能是支持细胞功能改善的证据。相比之下,顺铂诱导的血清促性腺激素和睾丸雄激素降低并未因任何一种阳离子预处理而减轻。可能需要进一步研究以确定ZnAc预处理在顺铂治疗期间对精子发生是否具有有益作用。